Abstract Our interest was so stimulated by the preliminary report of Maynard, entitled "Psoriasis Treated by Riboflavin,"1 that we undertook appraisal of the therapeutic effect of riboflavin in the treatment of psoriasis. Since Maynard's first report, we have studied with interest the positive and negative reports by Maynard, and by others. We summarize those reports briefly. Clinical Experience of Others Maynard's original study was based on response of 148 patients, 37 of whom were "healed"; 76 showed marked improvement (80% or better); 25 showed improvement (50% or more); 4 showed slight improvement (less than 50%); 6 failed to respond, and none worsened. "All these cases were given injections of riboflavin (5-10 mg. intramuscularly, usually once weekly) as a basic treatment. It has also been given orally in daily dosage coincident with the injections. In all cases local treatment has been dispensed with until proof of the patient's response References 1. Hoffmann-LaRoche, Inc., Nutley, N. J., supplied the Riboflavin 5′-phosphate (tablets and parenteral solution) and the Riboflavin U. S. P. 250 mg. tablets used in this study. 2. Microbiological assay of riboflavin (by modification of method of Snell and Strong15) was done by Hill Top Research Institute, Inc., Miamiville, Ohio. 3. Maynard, M. T. R.: Psoriasis Treated by Riboflavin , J. Invest. Dermat. 18:305 ( (April) ) 1952.Crossref 4. The 1952 Year Book of Dermatology , edited by M. B. Sulzberger and R. L. Baer, Chicago, The Year Book Publishers, Inc., 1952, p. 85. 5. Montilli, G., and Pisani, M.: Vitamin B2 in Psoriasis , Riforma Med. 68:205 ( (Feb. 20) ) 1954. 6. Montilli, G., and Pisani, M.: Vitamin B2 in the Treatment of Psoriasis , Atti Soc. ital. derm. sif. No. (1) Jan.-March, 1955 7. Minerva Derm. 30 ( (1) ) Supp. 8. Maynard, M. T. R.: Psoriasis: Treatment with Riboflavin , read before the 105th Annual Meeting of the American Medical Association, Chicago, June 14, 1956 9. J. A. M. A. 160:1490 ( (April 28) ) 1956. 10. Luscombe, H. A.: Riboflavin in Psoriasis , A. M. A. Arch. Dermat. 74:548 ( (Nov.) ) 1956.Crossref 11. de Preux, R.: Psoriasis et lactoflavine , Schweiz. med. Wchnschr. 72:596 ( (May 30) ) 1942. 12. Drobintzeva, A. V., and Plotnitzkaia, A. M.: La Vitamine B2 (riboflavine) dans les maladies de la peau , Ann. Dermat. et Syph. 78:86, 1951. 13. The Vitamins: Chemistry, Physiology, Pathology , edited by W. H. Sebrell Jr., and R. S. Harris, New York, Academic Press Inc., 1954. 14. Personal communication from Dr. S. Evert Svenson, Department of Clinical Research, Hoffmann-LaRoche, Inc., Nutley, N. J., May 21, 1954. 15. Forker, B. R., and Morgan, A. F.: Effect of Adrenocortical Hormone on the Riboflavin-Deficient Rat , J. Biol. Chem. 209:303 ( (Jan. 29) ) 1954. 16. Beveridge, J. M. R.; Connell, W. F., and Mayer, G. A.: Dietary Factors Affecting Plasma Cholesterol Level , Canad. J. Biochem. & Physiol. 34:441 ( (May) ) 1956. 17. Welsh, A. L.: Lupus Erythematosus: Treatment by Combined Use of Massive Amounts of Calcium Pantothenate or Panthenol with Synthetic Vitamin E , A. M. A. Arch. Dermat. & Syph. 65:137 ( (Feb.) ) 1952. 18. Welsh, A. L.: Granuloma Annulare: Response to Massive Dose Therapy of Vitamin E Combined with Pantothenic Acid Derivatives , A. M. A. Arch. Dermat. & Syph. 70:468 ( (Oct.) ) 1954. 19. Snell, E. E., and Strong, F. M.: Microbiological Assay of Riboflavin , Indust. & Engin. Chem. 11:346, 1939. 20. Gavin, G., and McHenry, E. W.: Inositol: A Lipotropic Factor , J. Biol. Chem. 139:485 ( (April 21) ) 1941. 21. McHenry, E. W., and Patterson, J. M.: Lipotropic Factors , Physiol. Rev. 24:128 ( (Jan.) ) 1944.
A.M.A. Archives of Dermatology – American Medical Association
Published: Nov 1, 1957